Enanta Pharmaceuticals Inc (ENTA)

11:11 AM

What analysts say about Enanta Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

11:11 AM

03:35 AM

What drives Enanta Pharmaceuticals Inc. stock priceTriple-digit growth rates - Autocar Professional

03:35 AM

Jul 22, 2025

Is Enanta Pharmaceuticals Inc. a good long term investmentHigh-yield capital appreciation - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Enanta Pharmaceuticals Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Enanta Pharmaceuticals at Baird’s Biotech: Strategic Virology and Immunology Shift - Investing.com Canada

Jul 22, 2025

Jul 18, 2025

why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser

Jul 18, 2025

Jul 18, 2025

Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser

Jul 18, 2025

Jul 16, 2025

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace

Jul 16, 2025

Jul 16, 2025

how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser

Jul 16, 2025

Jul 16, 2025

What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser

Jul 16, 2025

Jul 15, 2025

How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser

Jul 15, 2025

Jul 15, 2025

Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser

Jul 15, 2025

Jul 12, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

Jul 12, 2025

Jul 10, 2025

Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st

Jul 10, 2025

Jun 21, 2025

(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 21, 2025

Jun 14, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria

Jun 14, 2025

Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025

Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025

Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025

Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025

Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025

Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025

Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025

Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025

Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025

Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025